These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31406331)

  • 1. Cephamycins inhibit pathogen sporulation and effectively treat recurrent Clostridioides difficile infection.
    Srikhanta YN; Hutton ML; Awad MM; Drinkwater N; Singleton J; Day SL; Cunningham BA; McGowan S; Lyras D
    Nat Microbiol; 2019 Dec; 4(12):2237-2245. PubMed ID: 31406331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fidaxomicin inhibits spore production in Clostridium difficile.
    Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
    Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
    J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
    Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fate of ingested Clostridium difficile spores in mice.
    Howerton A; Patra M; Abel-Santos E
    PLoS One; 2013; 8(8):e72620. PubMed ID: 24023628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The early stage peptidoglycan biosynthesis Mur enzymes are antibacterial and antisporulation drug targets for recurrent Clostridioides difficile infection.
    Sapkota M; Marreddy RKR; Wu X; Kumar M; Hurdle JG
    Anaerobe; 2020 Feb; 61():102129. PubMed ID: 31760080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conserved oligopeptide permeases modulate sporulation initiation in Clostridium difficile.
    Edwards AN; Nawrocki KL; McBride SM
    Infect Immun; 2014 Oct; 82(10):4276-91. PubMed ID: 25069979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
    Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
    Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis, and Evaluation of Cephamycin-Based Antisporulation Agents targeting
    Cun WY; Bate CE; Srikhanta YN; Hutton ML; Webb CT; Revitt-Mills SA; Lyras D; McGowan S; Yu H; Keller PA; Pyne SG
    J Med Chem; 2024 Jan; 67(1):450-466. PubMed ID: 38112278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.
    Aldape MJ; Heeney DD; Bryant AE; Stevens DL
    J Antimicrob Chemother; 2015 Jan; 70(1):153-9. PubMed ID: 25151204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the impact of rpoB mutations on the in vitro and in vivo competitive fitness of Clostridium difficile and susceptibility to fidaxomicin.
    Kuehne SA; Dempster AW; Collery MM; Joshi N; Jowett J; Kelly ML; Cave R; Longshaw CM; Minton NP
    J Antimicrob Chemother; 2018 Apr; 73(4):973-980. PubMed ID: 29253242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.
    Allen CA; Babakhani F; Sears P; Nguyen L; Sorg JA
    Antimicrob Agents Chemother; 2013 Jan; 57(1):664-7. PubMed ID: 23147724
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Zhu D; Sorg JA; Sun X
    Front Cell Infect Microbiol; 2018; 8():29. PubMed ID: 29473021
    [No Abstract]   [Full Text] [Related]  

  • 14. A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity.
    Gebhart D; Lok S; Clare S; Tomas M; Stares M; Scholl D; Donskey CJ; Lawley TD; Govoni GR
    mBio; 2015 Mar; 6(2):. PubMed ID: 25805733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inducing and Quantifying Clostridium difficile Spore Formation.
    Shen A; Fimlaid KA; Pishdadian K
    Methods Mol Biol; 2016; 1476():129-42. PubMed ID: 27507338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Chicken IgY Specific to
    Pizarro-Guajardo M; Díaz-González F; Álvarez-Lobos M; Paredes-Sabja D
    Front Cell Infect Microbiol; 2017; 7():365. PubMed ID: 28856119
    [No Abstract]   [Full Text] [Related]  

  • 17. The Transcriptional Regulator Lrp Contributes to Toxin Expression, Sporulation, and Swimming Motility in
    Chen KY; Rathod J; Chiu YC; Chen JW; Tsai PJ; Huang IH
    Front Cell Infect Microbiol; 2019; 9():356. PubMed ID: 31681632
    [No Abstract]   [Full Text] [Related]  

  • 18. A cortex-specific penicillin-binding protein contributes to heat resistance in Clostridioides difficile spores.
    Alabdali YAJ; Oatley P; Kirk JA; Fagan RP
    Anaerobe; 2021 Aug; 70():102379. PubMed ID: 33940167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.
    Roder C; Athan E
    Drugs R D; 2020 Sep; 20(3):209-216. PubMed ID: 32377889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.
    Garneau JR; Valiquette L; Fortier LC
    BMC Infect Dis; 2014 Jan; 14():29. PubMed ID: 24422950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.